Tara Bancroft
Stock Analyst at TD Cowen
(4.78)
# 586
Out of 5,082 analysts
301
Total ratings
47.1%
Success rate
21.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tara Bancroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintained: Buy | $145 | $61.56 | +135.54% | 15 | Oct 22, 2026 | |
| GERN Geron | Maintained: Buy | $3 | $1.16 | +158.62% | 21 | Oct 22, 2026 | |
| INCY Incyte | Reiterated: Buy | $140 | $113.44 | +23.41% | 1 | Oct 21, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $155 → $160 | $138.08 | +15.87% | 18 | Oct 21, 2026 | |
| NBTX Nanobiotix | Reiterated: Buy | n/a | $25.83 | - | 4 | Sep 25, 2026 | |
| RCUS Arcus Biosciences | Initiated Coverage: Buy | n/a | $19.10 | - | 1 | Sep 16, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | n/a | $20.57 | - | 1 | Sep 9, 2026 | |
| EYPT EyePoint | Downgraded: Hold | $20 → $4 | $0.43 | +830.23% | 4 | Sep 1, 2026 | |
| FATE Fate Therapeutics | Reiterated: Hold | n/a | $2.07 | - | 14 | Aug 13, 2026 | |
| MGNX MacroGenics | Reiterated: Hold | n/a | $3.59 | - | 15 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.79 | - | 13 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.224 | - | 12 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $12 | $5.56 | +115.83% | 1 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.20 | - | 3 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.29 | - | 13 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $63.23 | +18.61% | 16 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $50 → $60 | $35.48 | +69.11% | 24 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $25.16 | - | 13 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $110 → $103 | $100.24 | +2.25% | 21 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $6.48 | +208.64% | 24 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $53.20 | +40.98% | 14 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.57 | - | 13 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $76.00 | - | 14 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $2.02 | - | 1 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $21.10 | - | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20.00 | $14.01 | +42.76% | 16 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.9621 | n/a | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $4.09 | n/a | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.17 | n/a | 2 | Jul 26, 2024 |
Celcuity
Oct 22, 2026
Maintained: Buy
Price Target: $145
Current: $61.56
Upside: +135.54%
Geron
Oct 22, 2026
Maintained: Buy
Price Target: $3
Current: $1.16
Upside: +158.62%
Incyte
Oct 21, 2026
Reiterated: Buy
Price Target: $140
Current: $113.44
Upside: +23.41%
Protagonist Therapeutics
Oct 21, 2026
Reiterated: Buy
Price Target: $155 → $160
Current: $138.08
Upside: +15.87%
Nanobiotix
Sep 25, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.83
Upside: -
Arcus Biosciences
Sep 16, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $19.10
Upside: -
Faeth Therapeutics
Sep 9, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $20.57
Upside: -
EyePoint
Sep 1, 2026
Downgraded: Hold
Price Target: $20 → $4
Current: $0.43
Upside: +830.23%
Fate Therapeutics
Aug 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.07
Upside: -
MacroGenics
Aug 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.59
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $10.79
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.224
Upside: -
Aug 11, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $5.56
Upside: +115.83%
Aug 10, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.20
Upside: -
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.29
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: $75
Current: $63.23
Upside: +18.61%
Aug 5, 2026
Rated: Buy
Price Target: $50 → $60
Current: $35.48
Upside: +69.11%
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.16
Upside: -
Aug 3, 2026
Downgraded: Hold
Price Target: $110 → $103
Current: $100.24
Upside: +2.25%
Aug 3, 2026
Reiterated: Buy
Price Target: $20
Current: $6.48
Upside: +208.64%
Aug 3, 2026
Reiterated: Buy
Price Target: $75
Current: $53.20
Upside: +40.98%
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.57
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $76.00
Upside: -
Jun 15, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $2.02
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.10
Upside: -
Feb 19, 2026
Reiterated: Buy
Price Target: $20.00
Current: $14.01
Upside: +42.76%
Mar 14, 2025
Rated: Hold
Price Target: n/a
Current: $0.9621
Upside: n/a
Aug 9, 2024
Rated: Buy
Price Target: n/a
Current: $4.09
Upside: n/a
Jul 26, 2024
Downgraded: Hold
Price Target: n/a
Current: $13.17
Upside: n/a